A G Hohmann
Overview
Explore the profile of A G Hohmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1663
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sciolino N, Bortolato M, Eisenstein S, Fu J, Oveisi F, Hohmann A, et al.
Neuroscience
. 2010 Apr;
168(2):371-86.
PMID: 20394803
Social deprivation in early life disrupts emotionality and attentional processes in humans. Rearing rats in isolation reproduces some of these abnormalities, which are attenuated by daily handling. However, the neurochemical...
2.
Guindon J, Hohmann A
Br J Pharmacol
. 2008 Feb;
153(7):1341-3.
PMID: 18297102
The endocannabinoid lipid 2-arachidonoylglycerol (2-AG) is deactivated by intracellular hydrolysis catalyzed by monoacylglycerol lipase. 2-AG also serves as a substrate for oxidative metabolism catalyzed by cyclooxygenase 2 (COX-2). However, products...
3.
Guindon J, Hohmann A
Br J Pharmacol
. 2007 Nov;
153(2):319-34.
PMID: 17994113
Cannabinoids suppress behavioural responses to noxious stimulation and suppress nociceptive transmission through activation of CB1 and CB2 receptor subtypes. CB1 receptors are expressed at high levels in the central nervous...
4.
Rahn E, Makriyannis A, Hohmann A
Br J Pharmacol
. 2007 Jun;
152(5):765-77.
PMID: 17572696
Background And Purpose: The ability of cannabinoids to suppress mechanical hypersensitivity (mechanical allodynia) induced by treatment with the chemotherapeutic agent vincristine was evaluated in rats. Sites of action were subsequently...
5.
Hohmann A
Br J Pharmacol
. 2007 Feb;
150(6):673-5.
PMID: 17293886
2-Arachidonoylglycerol (2-AG) is an endogenous cannabinoid (endocannabinoid) lipid whose functions remain poorly understood. Guindon and colleagues report the novel finding that exogenous application of 2-AG induces peripheral antinociceptive effects that...
6.
Gutierrez T, Farthing J, Zvonok A, Makriyannis A, Hohmann A
Br J Pharmacol
. 2006 Dec;
150(2):153-63.
PMID: 17160008
Background And Purpose: Effects of locally administered agonists and antagonists for cannabinoid CB(1) and CB(2) receptors on mechanical and thermal hypersensitivity were compared after the establishment of chronic inflammation. Experimental...
7.
Walker J, Hohmann A
Handb Exp Pharmacol
. 2006 Apr;
(168):509-54.
PMID: 16596786
A large body of literature indicates that cannabinoids suppress behavioral responses to acute and persistent noxious stimulation in animals. This review examines neuroanatomical, behavioral, and neurophysiological evidence supporting a role...
8.
Nackley A, Zvonok A, Makriyannis A, Hohmann A
J Neurophysiol
. 2004 Aug;
92(6):3562-74.
PMID: 15317842
Effects of the CB2-selective cannabinoid agonist AM1241 on activity evoked in spinal wide dynamic range (WDR) neurons by transcutaneous electrical stimulation were evaluated in urethane-anesthetized rats. Recordings were obtained in...
9.
Gutierrez T, Nackley A, Neely M, Freeman K, Edwards G, Hohmann A
Brain Res
. 2003 Sep;
987(2):176-85.
PMID: 14499961
The effects of neurotoxic destruction of catecholaminergic projections to the spinal cord on cannabinoid antinociception were examined in models of acute and tonic nociception. High performance liquid chromatography was used...
10.
Nackley A, Makriyannis A, Hohmann A
Neuroscience
. 2003 Jun;
119(3):747-57.
PMID: 12809695
Activation of cannabinoid CB(2) receptors attenuates thermal nociception in untreated animals while failing to produce centrally mediated effects such as hypothermia and catalepsy [Pain 93 (2001) 239]. The present study...